Global Prevalence of Polycystic Ovary Syndrome in Women Worldwide: a Comprehensive Systematic Review and Meta-analysis

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2024 Jun 26

PMID 38922413

Authors

Nader Salari

Anisodowleh Nankali

Amirhossaien Ghanbari

Sima Jafarpour

Hooman Ghasemi

Sadat Dokaneheifard

Masoud Mohammadi

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common metabolic disorder among women of reproductive age. Many factors are involved in the development of PCOS, among which genetic predisposition is probably the main contributor that is also influenced by lifestyle and environmental factors. This study aims to determine the prevalence of PCOS in different continents based on Rotterdam, AES and NIH diagnostic criteria.

Methods: We conducted a systematic review and meta-analysis to evaluate the prevalence of polycystic ovary syndrome in women according to (Preferred Reporting Items for Systematic Review and Meta-Analysis) PRISMA guidelines. PubMed, Scopus, Science Direct, Web of Science and Google Scholar databases were comprehensively searched until February 2021 for relevant articles. Heterogeneity between the studies was assessed using the I index. Begg and Mazumdar's test was used to evaluate publication bias.

Results: A total of 35 studies with 12,365,646 subjects were retrieved. The mean age ranged from 10-45 years. Global prevalence of PCOS was 9.2% (95% CI: 6.8-12.5%) based on meta-analysis, our results showed that the global prevalence of PCOS was 5.5% (95% CI: 3.9-7.7%) based on NIH criteria, 11.5 (95% CI: 6.6-19.4) based on Rotterdam criteria, and 7.1% (95% CI: 2.3-20.2%) based on AES criteria. According to self-report subgroup analysis, the prevalence of PCOS was found to be 11% (95% CI: 5.2-21.8%).

Conclusion: Based on the results of the present study, the prevalence of PCOS in the world was 9.2% (95% CI: 6.8-12.5%). According to the results of the present study and the high prevalence of PCOS, especially in the Africa continent, it is necessary for health systems to implement measures to timely prevent and treat this syndrome.

Citing Articles

Effect of Nigella sativa-L supplementation on glycemia in adolescent polycystic ovarian syndrome: secondary analysis of a randomized controlled trial study.

Mahmoudian A, Ashouri A, Mohammadzadeh F, Rahmani Bilandi R, Dashti S, Bahri N J Ovarian Res. 2025; 18(1):46.

PMID: 40055705 PMC: 11887340. DOI: 10.1186/s13048-025-01634-1.

Prevalence and risk factors of gestational diabetes mellitus among pregnant women in northern Vietnam: a cross-sectional study.

Le H, Nguyen T, Nguyen D, Sondergaard Linde D, Bygbjerg I, Sondergaard J Glob Health Action. 2025; 18(1):2460339.

PMID: 39925195 PMC: 11812109. DOI: 10.1080/16549716.2025.2460339.

Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome.

Nandakumar M, Das P, Sathyapalan T, Butler A, Atkin S Biomolecules. 2025; 15(1).

PMID: 39858399 PMC: 11763313. DOI: 10.3390/biom15010004.

Association of TCF7L2 genetic variants rs12255372 and rs7903146 with the polycystic ovary syndrome risk: systemic review and meta-analysis.

Shah I, Rashid R, Rashid H, Bhat A, Ganie M J Ovarian Res. 2025; 18(1):2.

PMID: 39762965 PMC: 11702189. DOI: 10.1186/s13048-024-01585-z.

Six-month randomized, placebo controlled trial of synbiotic supplementation in women with polycystic ovary syndrome undergoing lifestyle modifications.

Chudzicka-Strugala I, Kubiak A, Banaszewska B, Wysocka E, Zwozdziak B, Siakowska M Arch Gynecol Obstet. 2024; 311(2):499-506.

PMID: 39636391 PMC: 11890239. DOI: 10.1007/s00404-024-07833-3.

References

Ehrmann D . Polycystic ovary syndrome. N Engl J Med. 2005; 352(12):1223-36. DOI: 10.1056/NEJMra041536. View

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2008; 91(2):456-88. DOI: 10.1016/j.fertnstert.2008.06.035. View

El Hayek S, Bitar L, Hamdar L, Mirza F, Daoud G . Poly Cystic Ovarian Syndrome: An Updated Overview. Front Physiol. 2016; 7:124. PMC: 4820451. DOI: 10.3389/fphys.2016.00124. View

Bazarganipour F, Taghavi S, Montazeri A, Ahmadi F, Chaman R, Khosravi A . The impact of polycystic ovary syndrome on the health-related quality of life: A systematic review and meta-analysis. Iran J Reprod Med. 2015; 13(2):61-70. PMC: 4426142. View

Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H . The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand. 1999; 78(2):137-41. View

Kauffman R, Baker V, DiMarino P, Gimpel T, Castracane V . Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol. 2002; 187(5):1362-9. DOI: 10.1067/mob.2002.126650. View

Zhuang J, Liu Y, Xu L, Liu X, Zhou L, Tang L . Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecol Obstet Invest. 2014; 77(4):217-23. DOI: 10.1159/000358485. View

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

Asgharnia M, Mirblook F, Ahmad Soltani M . The Prevalence of Polycystic Ovary Syndrome (PCOS) in High School Students in Rasht in 2009 According to NIH Criteria. Int J Fertil Steril. 2014; 4(4):156-9. PMC: 4023501. View

10.

Azziz R, Woods K, Reyna R, Key T, Knochenhauer E, Yildiz B . The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89(6):2745-9. DOI: 10.1210/jc.2003-032046. View

11.

Boyle J, Cunningham J, ODea K, Dunbar T, Norman R . Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust. 2012; 196(1):62-6. DOI: 10.5694/mja11.10553. View

12.

Christensen S, Black M, Smith N, Martinez M, Jacobsen S, Porter A . Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013; 100(2):470-7. PMC: 3813299. DOI: 10.1016/j.fertnstert.2013.04.001. View

13.

Deswal R, Nanda S, Ghalaut V, Roy P, Dang A . Cross-sectional study of the prevalence of polycystic ovary syndrome in rural and urban populations. Int J Gynaecol Obstet. 2019; 146(3):370-379. DOI: 10.1002/ijgo.12893. View

14.

Esmaeilzadeh S, Delavar M, Amiri M, Khafri S, Pasha N . Polycystic ovary syndrome in Iranian adolescents. Int J Adolesc Med Health. 2014; 26(4):559-65. DOI: 10.1515/ijamh-2013-0335. View

15.

Hashemipour M, Faghihimani S, Zolfaghary B, Hovsepian S, Ahmadi F, Haghighi S . Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran. Horm Res. 2004; 62(6):278-82. DOI: 10.1159/000081842. View

16.

Kaewnin J, Vallibhakara O, Vallibhakara S, Wattanakrai P, Butsripoom B, Somsook E . Prevalence of polycystic ovary syndrome in Thai University adolescents. Gynecol Endocrinol. 2017; 34(6):476-480. DOI: 10.1080/09513590.2017.1409716. View

17.

Lauritsen M, Bentzen J, Pinborg A, Loft A, Forman J, Thuesen L . The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014; 29(4):791-801. DOI: 10.1093/humrep/det469. View

18.

Li R, Zhang Q, Yang D, Li S, Lu S, Wu X . Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013; 28(9):2562-9. DOI: 10.1093/humrep/det262. View

19.

Mehrabian F, Khani B, Kelishadi R, Ghanbari E . The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol. 2011; 62(3):238-42. View

20.

Michelmore K, Balen A, Dunger D, Vessey M . Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf). 2000; 51(6):779-86. DOI: 10.1046/j.1365-2265.1999.00886.x. View